Pharmacokinetic Study of a Soft Gelatin Capsule and a Solid-Supersaturatable SMEDDS Tablet of Dutasteride in Beagle Dogs
- 9 Downloads
Background and Objective
Dutasteride, an analog of testosterone, a 5α-reductase inhibitor is widely used in the treatment of moderate to severe symptomatic benign prostatic hyperplasia. The aim of this study was to compare the pharmacokinetic characteristics of dutasteride in beagle dogs after oral administration of a conventional soft gelatin capsule (Avodart®) and a novel solid-supersaturatable soft-microemulsifying drug delivery system (SMEDDS) tablet.
In this comparative dissolution study, the dissolution of dutasteride was pH-independent for both formulations. Noncompartmental analysis and modeling approaches were carried out to determine the pharmacokinetic parameters of dutasteride.
Approximately 90% of the drug dissolved in all media within 15 min, indicating that there was little difference in the dissolution rate of the solid-supersaturatable SMEDDS tablets and that of the commercial soft gelatin capsules. Using t test analysis, no statistically significant difference was detected in the pharmacokinetic parameters of the two formulations. The test/reference geometric mean ratios were 1.087 (90% confidence intervals 0.8529–1.3854) for the area under the plasma concentration versus time curve from 0 to the last time point (48 h) with a measurable concentration and 1.094 (90% confidence intervals 0.8909–1.3454) for maximum plasma concentration. Unfortunately, the bioequivalent criterium (0.8–1.25) was not met due to the small sample size, but the results of this study suggest a possible bioequivalence of dutasteride in the two formulations.
Based on the results of this study, the development of a tablet dosage form of dutasteride using a solid-supersaturatable SMEDDS should be considered for humans.
Compliance with Ethical Standards
This research was supported by Kyungsung University Research Grants in 2018.
Conflict of interest
The authors declare that they have no conflict of interest.
All animal procedures were approved by the Institutional Review Board of the KPC laboratory, a non-clinical contract research organization. The experiments were conducted in compliance with the Guidelines for the Care and Use of Laboratory Animals of the institute.
- 9.Baek I-H, Ha E-S, Yoo J-W, Jung Y, Kim M-S. Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasteride. Drug Des Dev Ther. 2015;9:3231.Google Scholar
- 25.Research CfDEa. Guidance for industry: bioanalytical method validation. US Food & Drug Administration. 2001.Google Scholar
- 26.WinNonlin. User’s guide (ver. 5.2). Pharsight Corporation: Mountain View, CA, USA. 2007.Google Scholar